Avalyn Pharma Inc. AVLN

AVLN Company Overview

Avalyn Pharma Inc. (Nasdaq: AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for the treatment of rare respiratory diseases. The company’s strategy centers on reformulating established systemic medicines into inhaled formulations designed to deliver higher drug concentrations directly to the lungs while potentially reducing systemic exposure and adverse effects. Avalyn primarily operates within the biotechnology and specialty pharmaceutical industries, with a focus on pulmonary hypertension and fibrotic lung diseases.

The company’s lead development programs include inhaled formulations targeting pulmonary arterial hypertension (PAH) and pulmonary fibrosis–related conditions. Avalyn evolved from earlier corporate entities focused on inhaled drug delivery technologies and has repositioned itself around pulmonary vascular and interstitial lung diseases. Its strategic differentiation is based on proprietary inhalation delivery approaches intended to improve efficacy, tolerability, and patient convenience relative to traditional oral or infused therapies.